We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01767948
Recruitment Status : Completed
First Posted : January 15, 2013
Last Update Posted : October 7, 2014
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of PCI 32765 in participants with mild, moderate, or severe hepatic impairment.

Condition or disease Intervention/treatment Phase
Hepatic Impairment Drug: PCI-32765 Phase 1

Detailed Description:
This is an open-label (all people know the identity of the intervention), single-dose, multi-center (study conducted at multiple sites), non-randomized study to access the pharmacokinetics of PCI-32765 in participants who either have mild, moderate, or severe hepatic impairment or qualify for the control group (normal liver function). The study mainly consists of 3 phases: screening phase (within 21 days prior to the first dose of study medication), treatment phase, and a follow up phase (10 to 12 days after the last dose of study medication). In the treatment phase, participants will receive single oral dose of PCI-32765 on Day 1. Liver impairment will be classified according to the Child-Pugh Classification of Severity of Liver Disease, as: normal, mild, moderate, and severe. Total 30 participants (24 with hepatic impairment [6 mild, 9 moderate and 9 severe] at baseline and 6 in the control group according to Child-Pugh criteria) will be enrolled. Participants in the control group will be enrolled after the participants with mild or moderate hepatic impairment have completed the study. Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination will be monitored throughout the study. The total duration of study for each participant will be approximately for 29 to 33 days.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment
Study Start Date : December 2012
Primary Completion Date : November 2013
Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Ibrutinib
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Patients with mild hepatic function
Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
Drug: PCI-32765
PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
Experimental: Patients with moderate hepatic function
Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
Drug: PCI-32765
PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
Experimental: Patients with severe hepatic function
Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
Drug: PCI-32765
PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
Experimental: Patients with normal hepatic function
Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
Drug: PCI-32765
PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.


Outcome Measures

Primary Outcome Measures :
  1. Maximum plasma concentration of PCI-32765 [ Time Frame: Predose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 16 hours, 24 hours, 36 hours, 48 hours, 72 hours, and 96 hours ]
  2. Area under the plasma concentration of PCI-32765 [ Time Frame: Predose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 16 hours, 24 hours, 36 hours, 48 hours, 72 hours, and 96 hours ]

Secondary Outcome Measures :
  1. Number of participants with adverse events [ Time Frame: up to Day 5 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable hepatic function as confirmed by the serum bilirubin and transaminase levels measured during screening and those measured within 48 hours prior to PCI-32765 administration
  • Must be hepatically impaired as defined by the Child-Pugh classification of severity of liver disease
  • Control group must have good health with normal liver function
  • Participants with controlled hypertension and those with problems directly associated with the primary diagnosis of hepatic impairment
  • Concomitant medications to treat underlying disease states or medical conditions related to hepatic impairment are allowed
  • Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

  • Clinically significant renal laboratory findings including serum creatinine more than 1.5 x the upper limit of normal (ULN) and/or calculated creatinine clearance of less than 60 ml per minute per 1.73 square meter
  • Clinically significant abnormal laboratory tests, physical examination, vital signs or electrocardiogram at screening or at admission to the study center
  • Antiviral therapy for active hepatitis infection at time of screening
  • Use of any anti-coagulation therapy including vitamin K antagonists, low molecular weight heparin, or other anticoagulants
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01767948


Locations
United States, California
Costa Mesa, California, United States
United States, Florida
Orlando, Florida, United States
United States, Tennessee
Knoxville, Tennessee, United States
United States, Texas
San Antonio, Texas, United States
Sponsors and Collaborators
Janssen Research & Development, LLC
Investigators
Study Director: Janssen Research & Development, LLC Clinical trial Janssen Research & Development, LLC
More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT01767948     History of Changes
Other Study ID Numbers: CR100944
PCI-32765CLL1006 ( Other Identifier: Janssen Research & Development, LLC )
First Posted: January 15, 2013    Key Record Dates
Last Update Posted: October 7, 2014
Last Verified: October 2014

Keywords provided by Janssen Research & Development, LLC:
Hepatic Impairment
PCI 32765
Metabolite PCI-45227
Pharmacokinetics

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases